Physician profile
Peter Yalch
NPI 1255388922
$12,956.55
in general payments reported to CMS, 2019-2025
53 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,674 · 2020: $1,596 · 2021: $2,510 · 2022: $1,817 · 2023: $1,908 · 2024: $1,558 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,150.65 | 2019-2025 | |
| Novo Nordisk INC | $1,113.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,003.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $885.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $809.02 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $798.37 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $785.70 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Amgen INC. | $738.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $649.13 | 2019-2025 | Steglatro, Gardasil 9, Belsomra |
| Astellas Pharma US INC | $592.25 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $522.29 | 2019-2022 | |
| Antares Pharma, INC. | $371.39 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $355.44 | 2020-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $323.11 | 2024-2025 | Voquezna |
| Bausch Health US, LLC | $234.68 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Yalch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.